OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Deng on the Benefits of Pirtobrutinib in CLL

May 4th 2024

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.

Dr Merchán on the Future Treatment of Advanced RCC

May 3rd 2024

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer

May 3rd 2024

Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS

May 3rd 2024

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Dr Iglesia on the COSMIC-312 Trial of Cabozantinib Plus Atezolizumab in HCC

May 3rd 2024

Michael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

May 3rd 2024

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Rosenberg on Toxicity Management With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 3rd 2024

Jonathan E. Rosenberg, MD, discusses toxicity management when administering enfortumab vedotin plus pembrolizumab in urothelial cancer.

Dr Garcia on the Future of the MELISA Trial in Ovarian Cancer

May 2nd 2024

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Dr Cobain on Endocrine Therapy–Based Treatment Strategies in HR+/HER2– Breast Cancer

May 2nd 2024

Erin Frances Cobain, MD, discusses optimal endocrine therapy–based treatment strategies in later-line settings for HR-positive/HER2-negative breast cancer.

Dr Lim on the Current Treatment Paradigm For Metastatic Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment options for patients with metastatic pancreatic cancer.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 2nd 2024

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+ Tumors

May 2nd 2024

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Dr Oluwole on the Use of CAR T-Cell Therapy in Autoimmune Disorders

May 2nd 2024

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.

Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic Malignancies

May 2nd 2024

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.

Dr Daver on the Targeted Therapy Development Pipeline in AML

May 1st 2024

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

Dr Jabbour on the Results of the PhALLCON Trial in Newly Diagnosed Ph+ ALL

May 1st 2024

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

Dr Tripathy on the HER2+ Breast Cancer Treatment Paradigm

May 1st 2024

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Dr Iyer on the Design of the COMMANDS Trial in Lower-Risk MDS With Anemia

May 1st 2024

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Dr Eroglu on Ceritinib With or Without Trametinib in Pretreated Advanced Melanoma

May 1st 2024

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.